Meeting
2022 ASCO Annual Meeting
Updated survival follow-up for phase I study of abexinostat with pazopanib in patients with solid tumor malignancies.
Authors
Erica S Tsang
University of California San Francisco, San Francisco, CA
Erica S Tsang , Rahul Raj Aggarwal , Scott Thomas , Mallika Sachdev Dhawan , Nela Pawlowska , Imke Heleen Bartelink , Jennifer A. Grabowsky , Thierry Marie Jahan , Thach-Giao Truong , Charles J. Ryan , Pamela N. Munster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Clinical Trial Registration Number
NCT01543763
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3150)
DOI
10.1200/JCO.2022.40.16_suppl.3150
Abstract #
3150
Poster Bd #
141
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.
First Author: Rahul Raj Aggarwal
Poster
2013 ASCO Annual Meeting
Phase I study of pazopanib (PAZ) in combination with PCI-24781 (PCI) in patients (pts) with metastatic solid tumors with new tumor proliferation imaging correlates in renal cell carcinoma (RCC) and sarcoma.
First Author: Thach-Giao Truong
Poster
2016 ASCO Annual Meeting
Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: A phase 1 study in advanced solid tumor malignancies.
First Author: Rahul Raj Aggarwal
Poster
2014 ASCO Annual Meeting
Phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (Pts) with metastatic solid tumors.
First Author: Rahul Raj Aggarwal